Taro Pharmaceutical Industries Ltd.
TARO · NYSE
3/31/2024 | 3/31/2023 | 3/31/2022 | 3/31/2021 | |
|---|---|---|---|---|
| Market Cap | $1,587 | $914 | $1,628 | $2,818 |
| - Cash | $363 | $154 | $251 | $605 |
| + Debt | $0 | $2 | $2 | $2 |
| Enterprise Value | $1,224 | $762 | $1,379 | $2,214 |
| Revenue | $629 | $573 | $561 | $549 |
| % Growth | 9.8% | 2.1% | 2.3% | – |
| Gross Profit | $305 | $268 | $293 | $297 |
| % Margin | 48.5% | 46.8% | 52.2% | 54% |
| EBITDA | $38 | $55 | $165 | -$414 |
| % Margin | 6.1% | 9.7% | 29.4% | -75.4% |
| Net Income | $54 | $25 | $58 | -$401 |
| % Margin | 8.6% | 4.4% | 10.4% | -73% |
| EPS Diluted | 1.43 | 0.68 | 1.55 | -10.49 |
| % Growth | 110.3% | -56.1% | 114.8% | – |
| Operating Cash Flow | $132 | $32 | -$159 | $46 |
| Capital Expenditures | -$54 | -$18 | -$12 | -$17 |
| Free Cash Flow | $78 | $14 | -$171 | $29 |